Core Insights - The company Vera has reported positive Phase III data for its treatment targeting IgA nephropathy, a type of kidney disease, which was presented at the ASN meeting and published in the New England Journal of Medicine [2] Group 1: Clinical Development - Vera has completed Phase III trials that yielded compelling results in the treatment of glomerulonephritis, specifically IgA nephropathy [2] - The company submitted its Biologics License Application (BLA) on November 7, with a review timeline of 2 months plus an additional 6 months [2] Group 2: Regulatory Milestones - Vera has received breakthrough designation for its treatment, which is expected to expedite the review process [2] - A PDUFA date is anticipated in early January, with a potential final decision expected in July [2]